Translating Pancreatic Risk into Personalized Medicine. A Meeting of Thought Lea

描述（由申请人提供）：我们提出了一个科学的课程和研讨会，题为：将胰腺炎风险转化为个性化 药思想领袖、翻译科学家和青年研究人员致力于合作努力的会议。该计划将有四个主要会议，旨在促进胰腺疾病的合作研究。该计划将开始通过NIDDK IBD遗传学联盟在IBD方面取得的进展进行审查和讨论。从该联盟中了解到的阳性和阴性病变都将适用于胰腺疾病的研究。这是一个非常成功的小组，他们一直致力于研究类似慢性胰腺炎的疾病。本次讨论之后， 审查NAPS2计划，有机会立即确定现有胰腺资源的优势和劣势，并帮助规划未来。第二次会议将侧重于国家消化疾病委员会确定的与胰腺疾病有关的更广泛的需求。本报告经过精心编写，是项目开发的重要文件。在对报告进行仔细审查和讨论后，计划或正在进行多中心试验的研究者将有机会介绍其各自研究的研究目标和具体目的。本次会议期间的讨论将侧重于确定正在满足的需求，并确定研究规划或机会中的主要差距。第三部分更具教学意义，旨在使临床研究人员了解流行病学，统计学，群体遗传学，系统生物学和选择治疗靶点（化学基因组学）的最新进展。此外，开发和使用生物标志物的问题

DESCRIPTION (provided by applicant): We are proposing a scientific Course and workshop entitled: Translating Pancreatitis Risk into Personalized Medicine. A Meeting of Thought Leaders, Translational Scientists and Young Investigators Dedicated to Cooperative Efforts. The program will have four major sessions aimed at stimulating collaborative research in pancreatic diseases. The program will begin by a review and discussion of the advances made in IBD through the NIDDK IBD-Genetics Consortium. It is intended that both positive and negative lesions learned from this consortium will be applicable to the study of pancreatic diseases. This has been a highly successful group who has been working on diseases that are similar to chronic pancreatitis. This discussion will be followed by a review of the NAPS2 program, with the opportunity to immediately determine the strengths and weaknesses of existing pancreatic resources, and to help in planning for the future. The second session will focus on broader needs identified by the National Commission on Digestive Diseases related to pancreatic disorders. This report has been carefully developed and serves as an important document for program development. After a careful review and discussion of the Report, the investigators who have planned, or who are conducting multi-center trials will have the opportunity to present the study goals and specific aims of their respective studies. Discussion during this session will focus on identifying the needs that are being met, and the identification of major gaps in research planning or opportunities. Session three is more didactic, with the intention of bringing clinical researchers up to date on advances in epidemiology, statistics, population genetics, systems biology and selecting therapeutic targets (chemical genomics). In addition, the issue of developing and using biomarkers